Thalidomide and its derivatives: new promise for multiple myeloma.
about
Venous and arterial thrombotic risks with thalidomide: evidence and practical guidanceThalidomide-associated thrombocytopenia.Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial.Systemic arthritis in children: a review of clinical presentation and treatmentThe novel compound STK405759 is a microtubule-targeting agent with potent and selective cytotoxicity against multiple myeloma in vitro and in vivo.
P2860
Thalidomide and its derivatives: new promise for multiple myeloma.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Thalidomide and its derivatives: new promise for multiple myeloma.
@ast
Thalidomide and its derivatives: new promise for multiple myeloma.
@en
type
label
Thalidomide and its derivatives: new promise for multiple myeloma.
@ast
Thalidomide and its derivatives: new promise for multiple myeloma.
@en
prefLabel
Thalidomide and its derivatives: new promise for multiple myeloma.
@ast
Thalidomide and its derivatives: new promise for multiple myeloma.
@en
P2860
P1433
P1476
Thalidomide and its derivatives: new promise for multiple myeloma.
@en
P2093
Donna Weber
P2860
P304
P356
10.1177/107327480301000504
P577
2003-09-01T00:00:00Z